drugset / Trial / NCT07821606
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase III study evaluating the efficacy of HS-20089 in combination with bevacizumab versus investigator's choice of platinum-based chemotherapy in combination with bevacizumab in participants with platinum-sensitive recurrent ovarian cancer (PSOC).
Timeline
- Start
- 2026-11-01
- Primary completion
- 2029-12-30
- Completion
- 2031-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | HS-20089 | Monoclonal antibody | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.